Shares of Soligenix Inc. gained 17% to 65 cents in premarket trading Tuesday after the company said regulators had cleared an investigational new drug application for a clinical trial examining its psoriasis treatment.
The company said the Food and Drug Administration had cleared the application for a Phase 2a trial designed to evaluate SGX302 as a topically applied treatment for mild to moderate psoriasis.
The trial will be a randomized, double-blind and placebo-controlled study of up to 32 adults with stable psoriasis covering between 2% and 30% of their bodies. Treatment will last for up to 18 weeks, Soligenix said.
Patient enrollment is expected to begin in the fourth quarter of 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.